Professor Humphrey Rang, President
Humphrey was a J H Burn research Fellow, at the Department of Pharmacology, Oxford, under the supervision of WDM Paton. His research interests are drug receptors, including the first successful receptor labelling studies, and kinetic analysis of ligand binding, ion channels, channel block and synaptic mechanisms at the neuromuscular junction and autonomic ganglia, pain, nociception and the identification of new targets for analgesic drugs. Humphrey has authored many research papers on these topics. Humphrey is also an author of Pharmacology (1987), now in its 7th Edition translated into 10 languages and winner of BMA Student Textbook Award (2007), and Drug Discovery and Development, winner of the Royal Society of Medicine Library Prize for Medical Book of the Year (2007).
Professor David Webb, President-Elect
David trained in medicine in London, started research training at the MRC Blood Pressure Unit in Glasgow, and completed research and clinical training in pharmacology & therapeutics in John Kelly‘s department at St George’s Hospital in London, working with Dr Joe Collier. His main interests are the pathophysiology and treatment of hypertension and chronic kidney disease, particularly focusing on endothelial function, and in the promotion of safe and effective prescribing. He is involved in running two Scottish translational medicine and therapeutics (TMAT) initiatives, supported by the Wellcome Trust and MRC.
Dr Robin Hiley, Honorary Treasurer
Robin trained under the supervision of Sir Arnold Burgen, first in Cambridge and then at the National Institute for Medical Research. He was a lecturer at the University of Liverpool before moving back to the University of Cambridge where he is now Reader in Vascular Pharmacology. His interests lie in the control of blood vessel tone by the endothelium and in the effects of lipid derivatives, such as the endocannabinoids, on cardiovascular function.
Professor Antony Galione, Co-Chair of CHOPT
Antony obtained a degree in Pharmacology from the University of Cambridge, and a PhD there under the supervision of Sir Michael Berridge. He has been at the Department of Pharmacology at the University of Oxford since 1991, and was elected to the Chair of Pharmacology in 2006 and has also been Head of Department since then. His research interests are in the field of calcium signalling, and in particular the role of calcium mobilizing messengers such as IP3, cyclic ADP-ribose and NAADP in receptor-effector coupling. He is a Wellcome Trust Senior Investigator and a Fellow of the Academy of Medical Sciences.
Professor Alyn Morice, Co-Chair of CHOPT
Professor Morice qualified at Cambridge University and after House jobs in London undertook research (MD) into the pharmacology of asthma at St Mary’s Hospital. As Clinical Lecturer at Addenbrooke’s Hospital Professor Morice developed his interest in cough, demonstrating cough hypersensitivity caused by ACE inhibitors. In 1989 Professor Morice was appointed as Senior Lecturer in Sheffield developing a Pulmonary Vascular service and the first UK Cough Clinic. In 1998 Professor Morice was appointed to the Foundation Chair in Respiratory Medicine in Hull University (now part of the Hull York Medical School). The Cough Clinic has become the largest centre within Europe with an international pattern of referral. Unique investigational strategies provide diagnosis and treatment advances which are incorporated into national and international guideline documents. Professor Morice has led the European Respiratory Society and British Thoracic Society Taskforces on Cough.
Professor Richard Green, Elected Trustee
Richard is currently Honorary Professor of Neuropharmacology at the University of Nottingham. His PhD was with Gerald Curzon and following two years at NIMH, Washington DC he joined David Grahame-Smith at the MRC Clinical Pharmacology Unit in Oxford, becoming Assistant Director in 1981. In 1986 he was appointed Director of the new Astra Neuroscience Research Unit in London, subsequently becoming Director, Global Discovery CNS & Pain Control for AstraZeneca. After retiring from AstraZeneca he has continued psychopharmacology research in Nottingham. He is a former President of the International Society for Serotonin Research and a President Emeritus of the British Pharmacological Society.
Dr Michael Seed, Elected Trustee
Mike trained as a pharmacologist at the University of Bath, and his PhD under the supervision of Ivor Williams. He joined the field of arthritis drug discovery, working on integrative arthritis and angiogenesis modelling at Hoechst and then Roussel. He continued his research into the modelling of angiogenesis, inflammation, immunity and arthritis at the William Harvey Research Institute, in collaboration with Biotech and a variety of drug targets. He has been lecturing on the Bart’s & the London MBBS and BMedSci courses, and is currently Reader in Pharmacology at the University of East London. Mike also serves on the BPS CHOPT Committee.
Dr Smita Price, Elected Trustee (Industry)
Smita is a neuropharmacologist with 20 years’ experience of working in the pharmaceutical industry. Smita obtained her BSc in Pharmacology at Cardiff University and gained her PhD in Physiology studying Movement disorders at Manchester University (supervised by Dr Paul Slater and Dr Alan Crossman). She spent 5 years as a Post-Doctoral fellow at the Institute of Psychiatry in London, specialising in epilepsy and schizophrenia. Smita then joined Merck Neuroscience Research centre in Harlow, where she gained over 15 years’ experience in CNS drug discovery and development. Smita is currently an independent pharmaceutical consultant.
Dr David Wood, Elected Trustee (Clinical)
David is a Consultant Physician and Clinical Toxicologist at Guy's and St Thomas' NHS Foundation Trust and King's Health Partners and an honorary senior lecture at King's College London. He studied medicine at the University of Bristol and his MD research and training in clinical pharmacology and therapeutics, clinical toxicology and general medicine in London. He has specialist clinical, research and academic interests in the epidemiology of use and acute toxicity ('harm') associated with the use of classical recreational drugs and novel psyschoactive substances ('legal highs'); he is an expert adviser to both the UK Advisory Council on the Misuse of Drugs (ACMD) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in these areas.
Professor Barbara McDermott, Vice President - Meetings (non-Trustee )
Barbara has been at Queen's University Belfast for most of her education and career, although has spent time away, firstly working in industry in Sheffield and later as a Postdoctoral Fellow in Bradford. Since appointment to an academic position at QUB in 1985, she has worked in other laboratories through exchange programmes with Germany and Japan, and during sabbatical terms in Canada and the United States. Research activities have focused on autocrine/paracrine control of cardiovascular dysfunction with special emphasis on the pharmacology of important peptide mediators, such as angiotensin II, endothelins, neuropeptide Y and the calcitonin gene-related peptide family. The contribution of oxidative stress to myocardial remodelling and interaction with peptide signalling pathways is of specific interest. Now Professor Emeritus, Barbara fulfils a further role in promoting gender equality in scientific careers and study of sex-gender in pursuit of research excellence.
Dr Ian McFadzean, Vice President - Academic Development (non-Trustee)
Ian graduated with a BSc in pharmacy from the University of Strathclyde before studying towards a PhD in pharmacology at the University of Cambridge under the supervision of Professors Ray Hill and Graeme Henderson. After a post-doc at University College London with Professor David Brown he gained a lectureship in pharmacology at King’s College London. He is now a Senior Lecturer in pharmacology at King’s and Dean of Undergraduate Studies within the School of Biomedical Sciences. He is interested in all aspects of university education and training in the biomedical sciences whilst his research focuses on calcium entry mechanisms in smooth muscle and other cells.
Professor Iain Greenwood, Vice President - Policy & Public Engagement (non-Trustee)
Iain obtained a First Class Honours Degree in Physiology and Pharmacology from the University of Hertfordshire in 1990 and completed a PhD in Physiology & Pharmacology from the University of Manchester in 1993 working in the Smooth Muscle Research Group under the supervision of Professor AH Weston. After a post-doctoral position at St George’s Hospital Medical School he was awarded a four-year Wellcome Trust Career Development Fellowship and spent part of it working with Professor Normand Leblanc at the Montreal Heart Institute. In 2001 he suspended his Fellowship to work with Professor Burt Horowitz in the Department of Physiology and Cell Biology at the University of Nevada Medical School, Reno, USA. After various faculty positions Iain Greenwood was appointed Professor of Vascular Pharmacology at St George’s, London in 2013. He also holds a visiting professorship in the Department of Biomedical Sciences (Heart and Circulatory Research Section) at the University of Copenhagen, Denmark following a long term collaboration with Professor Søren P Olesen. His main research interests are ion channel function in vascular and non-vascular physiology and the targeting of ion channels as therapeutic agents.
Professor Graeme Henderson, Vice President - Publications (non-Trustee)
Graeme trained in Aberdeen under the supervision of Professor Hans Kosterlitz and Prof John Hughes. He was an Assistant Professor at Loyola University in Chicago and a lecturer at the University of Cambridge before moving to the University of Bristol where he is Professor of Pharmacology. His research interests lie in the mechanism of action of opioid drugs and how the body adapts to their presence resulting in the development of tolerance and physical dependence. Graeme is a co-author of Rang & Dale’s Pharmacology 8th Edition.
Professor Munir Pirmohamed, Vice President - Clinical (non-Trustee)
Munir is the NHS Chair of Pharmacogenetics in the UK at the University of Liverpool, and is Director of the Wolfson Centre for Personalised Medicine. Professor Pirmohamed is a Commissioner on Human Medicines and is the Chair of its Pharmacovigilance Expert Advisory Group. He is also an inaugural NIHR Senior Investigator. Professor Pirmohamed's research focuses on individual variability in drug response with a view to evaluating the mechanisms, and identifying strategies to personalise medicines in order to optimise drug efficacy and minimise toxicity. The work spans the whole spectrum from discovery to implementation with the aim of developing the evidence base that can move discoveries from the lab to the clinic.
Emma Mason, Appointed Trustee (External Relations)
Emma graduated from Southampton University with a BA in Roman and Hellenic studies. She obtained a post-graduate diploma in journalism at City University and then worked as a reporter for regional and national newspapers. She moved into public relations, joining the Imperial Cancer Research Fund (now part of Cancer Research UK) before becoming a freelance media relations consultant specialising in the medical sciences. During the past couple of decades her clients have included a wide range of organisations, such as Oxford University Press, the National Translational Cancer Research Network and Queen Mary University of London, and European medical sciences societies and their conferences, such as those for cancer, cardiology, human reproduction and embryology, respiratory diseases, and neuroscience.